Neuropathic Pain Mechanisms and Imaging

Abstract

Molecular and cellular imaging of neuropathic pain, utilizing the myriad of receptors and inflammatory mediators involved in nociceptive activity, is a promising approach toward objectively identifying peripheral pain generators. Neuropathic conditions arise from injured and inflamed nerves, which have been shown to elaborate several molecular and cellular elements that give rise to the neuropathic phenotype and can be exploited for imaging purposes. As such, in vivo approaches to image neuropathic pain mechanisms include imaging voltage-gated sodium channels with radiolabeled saxitoxin, calcium signaling with manganese-enhanced magnetic resonance imaging, and inflammatory changes and nerve metabolism with ¹⁸F-fluorodeoxyglucose. Imaging approaches exploiting other mediators of nociceptive activity, such as substance P (neurokinin-1) receptor, sigma-1 receptor, and macrophages, have shown promising early advances in animal models. By combining the sensitivity and specificity of molecular imaging with the high anatomical, spatial and contrast resolution afforded by computed tomography and MRI, radiologists can potentially identify sites of nerve injury or neuroinflammation that are implicated as peripheral pain drivers with greater accuracy and confidence. In addition to guiding therapy, these approaches will aid in new drug designs for analgesia and more individualized treatment options.

Keywords

neuropathic pain - biological markers - musculoskeletal imaging - molecular imaging

• References

• 1 Institute of Medicine of the National Academies. Relieving pain in America: a blueprint for transforming prevention, care, education, and research. Available at: www.iom.edu/Reports/2011/Relieving-Pain-in-America-A-Blueprint-for-Transforming-Prevention-Care-Education-Research.aspx . Accessed April 15, 2013
• 2 Englund M, Guermazi A, Gale D , et al. Incidental meniscal findings on knee MRI in middle-aged and elderly persons. N Engl J Med 2008; 359 (11) 1108-1115
• 3 Jensen MC, Brant-Zawadzki MN, Obuchowski N, Modic MT, Malkasian D, Ross JS. Magnetic resonance imaging of the lumbar spine in people without back pain. N Engl J Med 1994; 331 (2) 69-73
• 4 Sher JS, Uribe JW, Posada A, Murphy BJ, Zlatkin MB. Abnormal findings on magnetic resonance images of asymptomatic shoulders. J Bone Joint Surg Am 1995; 77 (1) 10-15
• 5 Chou R, Fu R, Carrino JA, Deyo RA. Imaging strategies for low-back pain: systematic review and meta-analysis. Lancet 2009; 373 (9662) 463-472
• 6 Jarvik JG, Hollingworth W, Martin B , et al. Rapid magnetic resonance imaging vs radiographs for patients with low back pain: a randomized controlled trial. JAMA 2003; 289 (21) 2810-2818
• 7 Lurie JD, Birkmeyer NJ, Weinstein JN. Rates of advanced spinal imaging and spine surgery. Spine 2003; 28 (6) 616-620
• 8 Jensen MC, Brant-Zawadzki MN, Obuchowski N, Modic MT, Malkasian D, Ross JS. Magnetic resonance imaging of the lumbar spine in people without back pain. N Engl J Med 1994; 331 (2) 69-73
• 9 Matsumoto M, Fujimura Y, Suzuki N , et al. MRI of cervical intervertebral discs in asymptomatic subjects. J Bone Joint Surg Br 1998; 80 (1) 19-24
• 10 Needell SD, Zlatkin MB, Sher JS, Murphy BJ, Uribe JW. MR imaging of the rotator cuff: peritendinous and bone abnormalities in an asymptomatic population. AJR Am J Roentgenol 1996; 166 (4) 863-867
• 11 Pope Jr TL. Abnormal findings on magnetic resonance images of asymptomatic shoulders. J Bone Joint Surg Am 1996; 78 (4) 633-635
• 12 Sher JS, Uribe JW, Posada A, Murphy BJ, Zlatkin MB. Abnormal findings on magnetic resonance images of asymptomatic shoulders. J Bone Joint Surg Am 1995; 77 (1) 10-15
• 13 Moisset X, Bouhassira D. Brain imaging of neuropathic pain. Neuroimage 2007; 37 (Suppl. 01) S80-S88
• 14 Peyron R, Laurent B, García-Larrea L. Functional imaging of brain responses to pain. A review and meta-analysis (2000). Neurophysiol Clin 2000; 30 (5) 263-288
• 15 Kuner R. Central mechanisms of pathological pain. Nat Med 2010; 16 (11) 1258-1266
• 16 Loeser JD, Treede RD. The Kyoto protocol of IASP Basic Pain Terminology. Pain 2008; 137 (3) 473-477
• 17 Scholz J, Woolf CJ. The neuropathic pain triad: neurons, immune cells and glia. Nat Neurosci 2007; 10 (11) 1361-1368
• 18 Costigan M, Scholz J, Woolf CJ. Neuropathic pain: a maladaptive response of the nervous system to damage. Annu Rev Neurosci 2009; 32: 1-32
• 19 Sweitzer SM, Hickey WF, Rutkowski MD, Pahl JL, DeLeo JA. Focal peripheral nerve injury induces leukocyte trafficking into the central nervous system: potential relationship to neuropathic pain. Pain 2002; 100 (1-2) 163-170
• 20 Hu P, McLachlan EM. Distinct functional types of macrophage in dorsal root ganglia and spinal nerves proximal to sciatic and spinal nerve transections in the rat. Exp Neurol 2003; 184 (2) 590-605
• 21 Watkins LR, Maier SF. Glia: a novel drug discovery target for clinical pain. Nat Rev Drug Discov 2003; 2 (12) 973-985
• 22 Hu P, Bembrick AL, Keay KA, McLachlan EM. Immune cell involvement in dorsal root ganglia and spinal cord after chronic constriction or transection of the rat sciatic nerve. Brain Behav Immun 2007; 21 (5) 599-616
• 23 Papadopoulos V, Baraldi M, Guilarte TR , et al. Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol Sci 2006; 27 (8) 402-409
• 24 Papadopoulos V, Lecanu L. Translocator protein (18 kDa) TSPO: an emerging therapeutic target in neurotrauma. Exp Neurol 2009; 219 (1) 53-57
• 25 Garvey LJ, Pavese N, Politis M , et al. Increased microglia activation in neurologically asymptomatic HIV-infected patients receiving effective ART. AIDS 2014; 28 (1) 67-72
• 26 Golla S, Boellaard R, Oikonen V , et al. Quantification of [18F]DPA-714 binding in the human brain: initial studies in healthy controls and Alzheimer's disease patients. J Cereb Blood Flow Metab 2015; ; February 4 (Epub ahead of print)
• 27 Brody AL, Okita K, Shieh J , et al. Radiation dosimetry and biodistribution of the translocator protein radiotracer [(11)C]DAA1106 determined with PET/CT in healthy human volunteers. Nucl Med Biol 2014; 41 (10) 871-875
• 28 Owen DR, Guo Q, Kalk NJ , et al. Determination of [(11)C]PBR28 binding potential in vivo: a first human TSPO blocking study. J Cereb Blood Flow Metab 2014; 34 (6) 989-994
• 29 Imamoto N, Momosaki S, Fujita M , et al. [11C]PK11195 PET imaging of spinal glial activation after nerve injury in rats. Neuroimage 2013; 79: 121-128
• 30 Díaz JL, Zamanillo D, Corbera J , et al. Selective sigma-1 (sigma1) receptor antagonists: emerging target for the treatment of neuropathic pain. Cent Nerv Syst Agents Med Chem 2009; 9 (3) 172-183
• 31 Gannon CJ, Malone DL, Napolitano LM. Reduction of IL-10 and nitric oxide synthesis by SR31747A (sigma ligand) in RAW murine macrophages. Surg Infect (Larchmt) 2001; 2 (4) 267-272 ; discussion 273
• 32 Palacios G, Muro A, Verdú E, Pumarola M, Vela JM. Immunohistochemical localization of the sigma1 receptor in Schwann cells of rat sciatic nerve. Brain Res 2004; 1007 (1–2) 65-70
• 33 Woolf CJ ; American College of Physicians; American Physiological Society. Pain: moving from symptom control toward mechanism-specific pharmacologic management. Ann Intern Med 2004; 140 (6) 441-451
• 34 Behera D, Shen B, James ML , et al. Radiolabeled sigma-1 receptor ligand detects peripheral neuroinflammation in a neuropathic pain model using PET/MRI. In: Pichler B, , ed. 2012 World Molecular Imaging Congress. Dublin, Ireland: World Molecular Imaging Society; 2012: SS123
• 35 James ML, Shen B, Zavaleta CL , et al. New positron emission tomography (PET) radioligand for imaging σ-1 receptors in living subjects. J Med Chem 2012; 55 (19) 8272-8282
• 36 Ghanouni P, Behera D, Xie J, Chen X, Moseley M, Biswal S. In vivo USPIO magnetic resonance imaging shows that minocycline mitigates macrophage recruitment to a peripheral nerve injury. Mol Pain 2012; 8: 49
• 37 Woolf CJ ; American College of Physicians; American Physiological Society. Pain: moving from symptom control toward mechanism-specific pharmacologic management. Ann Intern Med 2004; 140 (6) 441-451
• 38 Dirig DM, Yaksh TL. Thermal hyperalgesia in rat evoked by intrathecal substance P at multiple stimulus intensities reflects an increase in the gain of nociceptive processing. Neurosci Lett 1996; 220 (2) 93-96
• 39 Honor P, Menning PM, Rogers SD , et al. Spinal substance P receptor expression and internalization in acute, short-term, and long-term inflammatory pain states. J Neurosci 1999; 19 (17) 7670-7678
• 40 Ji RR, Befort K, Brenner GJ, Woolf CJ. ERK MAP kinase activation in superficial spinal cord neurons induces prodynorphin and NK-1 upregulation and contributes to persistent inflammatory pain hypersensitivity. J Neurosci 2002; 22 (2) 478-485
• 41 Breeman WA, VanHagen MP, Visser-Wisselaar HA , et al. In vitro and in vivo studies of substance P receptor expression in rats with the new analog [indium-111-DTPA-Arg1]substance P. J Nucl Med 1996; 37 (1) 108-117
• 42 Chin FT, Morse CL, Shetty HU, Pike VW. Automated radiosynthesis of [18F]SPA-RQ for imaging human brain NK1 receptors with PET. J Labelled Comp Radiopharm 2006; 49: 17-31
• 43 Bergström M, Hargreaves RJ, Burns HD , et al. Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant. Biol Psychiatry 2004; 55 (10) 1007-1012
• 44 Woolf CJ, Salter MW. Neuronal plasticity: increasing the gain in pain. Science 2000; 288 (5472) 1765-1769
• 45 Willoch F, Schindler F, Wester HJ , et al. Central poststroke pain and reduced opioid receptor binding within pain processing circuitries: a [11C]diprenorphine PET study. Pain 2004; 108 (3) 213-220
• 46 Wester HJ, Willoch F, Tölle TR , et al. 6-O-(2-[18F]fluoroethyl)-6-O-desmethyldiprenorphine ([18F]DPN): synthesis, biologic evaluation, and comparison with [11C]DPN in humans. J Nucl Med 2000; 41 (7) 1279-1286
• 47 Galynker I, Schlyer DJ, Dewey SL , et al. Opioid receptor imaging and displacement studies with [6-O-[11C] methyl]buprenorphine in baboon brain. Nucl Med Biol 1996; 23 (3) 325-331
• 48 Yang DJ, Bryant J, Chang JY , et al. Assessment of cyclooxygense-2 expression with 99mTc-labeled celebrex. Anticancer Drugs 2004; 15 (3) 255-263
• 49 McCarthy TJ, Sheriff AU, Graneto MJ, Talley JJ, Welch MJ. Radiosynthesis, in vitro validation, and in vivo evaluation of 18F-labeled COX-1 and COX-2 inhibitors. J Nucl Med 2002; 43 (1) 117-124
• 50 de Vries EF, van Waarde A, Buursma AR, Vaalburg W. Synthesis and in vivo evaluation of 18F-desbromo-DuP-697 as a PET tracer for cyclooxygenase-2 expression. J Nucl Med 2003; 44 (10) 1700-1706
• 51 Black JA, Nikolajsen L, Kroner K, Jensen TS, Waxman SG. Multiple sodium channel isoforms and mitogen-activated protein kinases are present in painful human neuromas. Ann Neurol 2008; 64 (6) 644-653
• 52 Pertin M, Ji RR, Berta T , et al. Upregulation of the voltage-gated sodium channel β2 subunit in neuropathic pain models: characterization of expression in injured and non-injured primary sensory neurons. J Neurosci 2005; 25 (47) 10970-10980
• 53 Hoehne A, Behera D, Parsons WH , et al. A 18F-labeled saxitoxin derivative for in vivo PET-MR imaging of voltage-gated sodium channel expression following nerve injury. J Am Chem Soc 2013; 135 (48) 18012-18015
• 54 Jacobs KE, Behera D, Rosenberg J , et al. Oral manganese as an MRI contrast agent for the detection of nociceptive activity. NMR Biomed 2012; 25 (4) 563-569
• 55 Behera D, Behera S, Jacobs KE, Biswal S. Bilateral peripheral neural activity observed in vivo following unilateral nerve injury. Am J Nucl Med Mol Imaging 2013; 3 (3) 282-290
• 56 Behera D, Jacobs KE, Behera S, Rosenberg J, Biswal S. (18)F-FDG PET/MRI can be used to identify injured peripheral nerves in a model of neuropathic pain. J Nucl Med 2011; 52 (8) 1308-1312
• 57 Cheng G, Chamroonrat W, Bing Z, Huang S, Zhuang H. Elevated FDG activity in the spinal cord and the sciatic nerves due to neuropathy. Clin Nucl Med 2009; 34 (12) 950-951